BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bello RJ, Cooney CM, Melamed E, Follmar K, Yenokyan G, Leatherman G, Shah AA, Wigley FM, Hummers LK, Lifchez SD. The Therapeutic Efficacy of Botulinum Toxin in Treating Scleroderma-Associated Raynaud's Phenomenon: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Arthritis Rheumatol 2017;69:1661-9. [PMID: 28426903 DOI: 10.1002/art.40123] [Cited by in Crossref: 42] [Cited by in F6Publishing: 46] [Article Influence: 8.4] [Reference Citation Analysis]
Number Citing Articles
1 Roustit M, Jullien A, Jambon-barbara C, Goudon H, Blaise S, Cracowski J, Khouri C. Placebo response in Raynaud's Phenomenon clinical trials: the prominent role of regression towards the mean. Seminars in Arthritis and Rheumatism 2022. [DOI: 10.1016/j.semarthrit.2022.152087] [Reference Citation Analysis]
2 Winayanuwattikun W, Vachiramon V. Botulinum Toxin Type A for the Treatment of Skin Ulcers: A Review Article. Toxins (Basel) 2022;14:406. [PMID: 35737067 DOI: 10.3390/toxins14060406] [Reference Citation Analysis]
3 Lewandowski M, Świerczewska Z, Barańska-rybak W. Off-Label Use of Botulinum Toxin in Dermatology—Current State of the Art. Molecules 2022;27:3143. [DOI: 10.3390/molecules27103143] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Zanin-Silva DC, Santana-Gonçalves M, Kawashima-Vasconcelos MY, Oliveira MC. Management of Endothelial Dysfunction in Systemic Sclerosis: Current and Developing Strategies. Front Med (Lausanne) 2021;8:788250. [PMID: 35004754 DOI: 10.3389/fmed.2021.788250] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Herrick AL. Raynaud's phenomenon and digital ulcers: advances in evaluation and management. Curr Opin Rheumatol 2021;33:453-62. [PMID: 34420003 DOI: 10.1097/BOR.0000000000000826] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Hachulla E, Agard C, Allanore Y, Avouac J, Bader-Meunier B, Belot A, Berezne A, Bouthors AS, Condette-Wojtasik G, Constans J, De Groote P, Diot E, Dumas F, Jego P, Joly F, Launay D, Le Guern V, Le Quintrec JS, Lescaille G, Meune C, Moulin B, Nguyen C, Omeish N, Pene F, Richard MA, Rochefort J, Roren A, Sitbon O, Sobanski V, Truchetet ME, Mouthon L; Collaborators. French recommendations for the management of systemic sclerosis. Orphanet J Rare Dis 2021;16:322. [PMID: 34304732 DOI: 10.1186/s13023-021-01844-y] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
7 Haque A, Hughes M. Raynaud's phenomenon. Clin Med (Lond) 2020;20:580-7. [PMID: 33199324 DOI: 10.7861/clinmed.2020-0754] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
8 Ennis D, Ahmad Z, Anderson MA, Johnson SR. Botulinum toxin in the management of primary and secondary Raynaud's phenomenon. Best Pract Res Clin Rheumatol 2021;:101684. [PMID: 33965340 DOI: 10.1016/j.berh.2021.101684] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
9 Quintana Castanedo L, Feito Rodríguez M, Nieto Rodríguez D, Maseda Pedrero R, Chiloeches Fernández C, de Lucas Laguna R. Botulinum Toxin A Treatment for Primary and Secondary Raynaud's Phenomenon in Teenagers. Dermatol Surg 2021;47:61-4. [PMID: 32371783 DOI: 10.1097/DSS.0000000000002397] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Klein-Weigel P, Sander O, Reinhold S, Nielitz J, Steindl J, Richter J. Raynaud's Phenomenon: A Vascular Acrosyndrome That Requires Long-Term Care. Dtsch Arztebl Int 2021;118:arztebl. [PMID: 33632387 DOI: 10.3238/arztebl.m2021.0023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
11 Bernstein DN, Cliburn JA, Lachant DJ, White RJ, Hammert WC. Evaluation of Clinical Recovery After Surgical Treatment for Hand Ischemia From Vasospastic and Occlusive Disease Using PROMIS. Hand (N Y) 2021;:1558944721999727. [PMID: 33789521 DOI: 10.1177/1558944721999727] [Reference Citation Analysis]
12 Connolly MK. Systemic sclerosis (scleroderma): remaining challenges. Ann Transl Med 2021;9:438. [PMID: 33842659 DOI: 10.21037/atm-20-5449] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Martina E, Diotallevi F, Radi G, Campanati A, Offidani A. Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review. Toxins (Basel) 2021;13:120. [PMID: 33562846 DOI: 10.3390/toxins13020120] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
14 Goldberg SH, Akoon A, Kirchner HL, Deegan J. The Effects of Botulinum Toxin A on Pain in Ischemic Vasospasm. J Hand Surg Am 2021;46:513.e1-513.e12. [PMID: 33431193 DOI: 10.1016/j.jhsa.2020.11.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Herrick AL, Shukla R, Watson REB. Frontiers in translational systemic sclerosis research: A focus on the unmet 'cutaneous' clinical needs (Viewpoint). Exp Dermatol 2020;29:1144-53. [DOI: 10.1111/exd.14179] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
16 Alster TS, Harrison IS. Alternative Clinical Indications of Botulinum Toxin. Am J Clin Dermatol 2020;21:855-80. [PMID: 32651806 DOI: 10.1007/s40257-020-00532-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
17 Beldner S, Rabinovich RV, Polatsch DB. Scleroderma of the Hand: Evaluation and Treatment. J Am Acad Orthop Surg 2020;28:e686-95. [PMID: 32769717 DOI: 10.5435/JAAOS-D-19-00547] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Pauling JD, Hackett N, Guida A, Merkel PA. Performance of laser-derived imaging for assessing digital perfusion in clinical trials of systemic sclerosis-related digital vasculopathy: A systematic literature review. Seminars in Arthritis and Rheumatism 2020;50:1114-30. [DOI: 10.1016/j.semarthrit.2020.06.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
19 Gallegos JE, Inglesby DC, Young ZT, Herrera FA. Botulinum Toxin for the Treatment of Intractable Raynaud Phenomenon. J Hand Surg Am 2021;46:54-9. [PMID: 32948347 DOI: 10.1016/j.jhsa.2020.07.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
20 Habib SM, Brenninkmeijer EEA, Vermeer MH, de Vries-Bouwstra JK, Velthuis PJ. Botulinum toxin type A in the treatment of Raynaud's phenomenon. Dermatol Ther 2020;33:e14182. [PMID: 32794364 DOI: 10.1111/dth.14182] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
21 Varghese B, Chew E, Konig MF. Digit Ulcerations in a Young Woman. JAMA 2020;324:385-6. [PMID: 32568390 DOI: 10.1001/jama.2020.6084] [Reference Citation Analysis]
22 McMahan ZH, Volkmann ER. An update on the pharmacotherapeutic options and treatment strategies for systemic sclerosis. Expert Opin Pharmacother 2020;21:2041-56. [PMID: 32674612 DOI: 10.1080/14656566.2020.1793960] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
23 Herrick AL, Dinsdale G, Murray A. New perspectives in the imaging of Raynaud's phenomenon. Eur J Rheumatol 2020;7:S212-21. [PMID: 33164735 DOI: 10.5152/eurjrheum.2020.19124] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
24 Quintana Castanedo L, Feito Rodríguez M, Maseda Pedrero R, Chiloeches Fernández C, de Lucas Laguna R. Ischemic ulcers of the toes secondary to Raynaud's phenomenon in a child successfully treated with botulinum toxin. Pediatr Dermatol 2020;37:681-3. [PMID: 32212180 DOI: 10.1111/pde.14160] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Guerra MG, Fonseca DGD, Samões B, Videira T, Pinto P. Is Botulinum Toxin Useful in Systemic Sclerosis Related Peripheral Vasculopathy? A Literature Review. Reumatol Clin (Engl Ed) 2021;17:357-63. [PMID: 32591260 DOI: 10.1016/j.reuma.2020.04.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Nagarajan M, McArthur P. Targeted high concentration botulinum toxin A injections in patients with Raynaud's phenomenon: a retrospective single-centre experience. Rheumatol Int 2021;41:943-9. [PMID: 32447423 DOI: 10.1007/s00296-020-04606-4] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
27 Winter AR, Camargo Macias K, Kim S, Sami N, Weinstein D. The Effect of Abobotulinum Toxin A on the Symptoms of Raynaud's Phenomenon: A Case Series. Cureus 2020;12:e8235. [PMID: 32582494 DOI: 10.7759/cureus.8235] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Hughes M, Alcacer-pitarch B, Allanore Y, Baron M, Boin F, Bruni C, Chung L, Del Galdo F, Denton CP, Matucci-cerinic M. Digital ulcers: should debridement be a standard of care in systemic sclerosis? The Lancet Rheumatology 2020;2:e302-7. [DOI: 10.1016/s2665-9913(19)30164-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Tapia-Haro RM, García-Ríos MC, Toledano-Moreno S, Casas-Barragán A, Castro-Sánchez AM, Aguilar-Ferrándiz ME. The complementary effects of galvanic current electrical stimulation associated with conservative treatment to increase vasodilation in patients with Raynaud's phenomenon: a randomized trial. Clin Rehabil 2020;34:595-606. [PMID: 32141306 DOI: 10.1177/0269215520907652] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
30 Del Galdo F, Hartley C, Allanore Y. Randomised controlled trials in systemic sclerosis: patient selection and endpoints for next generation trials. The Lancet Rheumatology 2020;2:e173-84. [DOI: 10.1016/s2665-9913(20)30007-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
31 Herrick AL, Wigley FM. Raynaud's phenomenon. Best Pract Res Clin Rheumatol 2020;34:101474. [PMID: 32007400 DOI: 10.1016/j.berh.2019.101474] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
32 Khouri C, Lepelley M, Bailly S, Blaise S, Herrick AL, Matucci-cerinic M, Allanore Y, Trinquart L, Cracowski J, Roustit M. Comparative efficacy and safety of treatments for secondary Raynaud's phenomenon: a systematic review and network meta-analysis of randomised trials. The Lancet Rheumatology 2019;1:e237-46. [DOI: 10.1016/s2665-9913(19)30079-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
33 Dhaliwal K, Griffin MF, Salinas S, Howell K, Denton CP, Butler PEM. Optimisation of botulinum toxin type a treatment for the management of Raynaud's phenomenon using a dorsal approach: a prospective case series. Clin Rheumatol 2019;38:3669-76. [PMID: 31482318 DOI: 10.1007/s10067-019-04762-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
34 Pauling JD, Hughes M, Pope JE. Raynaud's phenomenon-an update on diagnosis, classification and management. Clin Rheumatol 2019;38:3317-30. [PMID: 31420815 DOI: 10.1007/s10067-019-04745-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 29] [Article Influence: 7.3] [Reference Citation Analysis]
35 Williams AA, Carl HM, Lifchez SD. The Scleroderma Hand: Manifestations of Disease and Approach to Management. J Hand Surg Am 2018;43:550-7. [PMID: 29691079 DOI: 10.1016/j.jhsa.2018.03.021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
36 Herrick AL. Raynaud’s phenomenon. Journal of Scleroderma and Related Disorders 2019;4:89-101. [DOI: 10.1177/2397198319826467] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
37 Fernández-codina A, Cañas-ruano E, Pope JE. Management of Raynaud’s phenomenon in systemic sclerosis—a practical approach. Journal of Scleroderma and Related Disorders 2019;4:102-10. [DOI: 10.1177/2397198318823951] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
38 Medina S, Gómez-Zubiaur A, Valdeolivas-Casillas N, Polo-Rodríguez I, Ruíz L, Izquierdo C, Guirado C, Cabrera A, Trasobares L. Botulinum toxin type A in the treatment of Raynaud's phenomenon: A three-year follow-up study. Eur J Rheumatol 2018;5:224-9. [PMID: 30501848 DOI: 10.5152/eurjrheum.2018.18013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
39 Boukovalas S, Mays AC, Selber JC. Botulinum Toxin Injection for Lower Face and Oral Cavity Raynaud Phenomenon After Mandibulectomy, Free Fibula Reconstruction, and Radiation Therapy. Ann Plast Surg 2019;82:53-4. [PMID: 30260839 DOI: 10.1097/SAP.0000000000001622] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
40 Merz EL, Assassi S, Malcarne VL. Pain and Its Management in Systemic Sclerosis. Curr Treat Options in Rheum 2018;4:255-67. [DOI: 10.1007/s40674-018-0104-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Hinze AM, Wigley FM. Pharmacotherapy Options in the Management of Raynaud's Phenomenon. Curr Treatm Opt Rheumatol 2018;4:235-54. [PMID: 31538045 DOI: 10.1007/s40674-018-0102-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
42 Pauling JD. The challenge of establishing treatment efficacy for cutaneous vascular manifestations of systemic sclerosis. Expert Rev Clin Immunol 2018;14:431-42. [PMID: 29641934 DOI: 10.1080/1744666X.2018.1464390] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
43 Pearson DR, Werth VP, Pappas-Taffer L. Systemic sclerosis: Current concepts of skin and systemic manifestations. Clin Dermatol 2018;36:459-74. [PMID: 30047430 DOI: 10.1016/j.clindermatol.2018.04.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
44 Stringer T, Femia AN. Raynaud's phenomenon: Current concepts. Clin Dermatol 2018;36:498-507. [PMID: 30047433 DOI: 10.1016/j.clindermatol.2018.04.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
45 Dhaliwal K, Griffin M, Denton CP, Butler PEM. The novel use of botulinum toxin A for the treatment of Raynaud's phenomenon in the toes. BMJ Case Rep 2018;2018:bcr-2017-219348. [PMID: 29525756 DOI: 10.1136/bcr-2017-219348] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
46 Motegi SI, Sekiguchi A, Saito S, Ishibuchi H, Kishi C, Yasuda M, Ishikawa O. Successful treatment of Raynaud's phenomenon and digital ulcers in systemic sclerosis patients with botulinum toxin B injection: Assessment of peripheral vascular disorder by angiography and dermoscopic image of nail fold capillary. J Dermatol 2018;45:349-52. [PMID: 29164658 DOI: 10.1111/1346-8138.14140] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]